Literature DB >> 6424781

A specific IgG in Graves' ophthalmopathy and its relation to retro-orbital and thyroid autoimmunity.

P Kendall-Taylor, S Atkinson, M Holcombe.   

Abstract

An IgG (ophthalmopathic immunoglobulin) that binds to retro-orbital antigen was identified in serum from patients with active Graves' ophthalmopathy, and its nature and specificity were investigated. Dose related binding of this immunoglobulin to retro-orbital antigens prepared from guinea pig harderian gland or porcine eye muscle was found, which could be abolished by prior incubation with antigen. The immunoglobulin did not bind to thyroid membranes, thyroid microsomes, or thyroglobulin or interact with liver, skeletal muscle, or fat membranes. Serum with high activity of thyrotrophin binding inhibiting immunoglobulin did not react with retro-orbital antigen, and this activity was not affected by preincubation of the serum with retro-orbital antigen. Thyroid stimulating hormone was also without effect on retro-orbital antigen. It is concluded that Graves' ophthalmopathy is associated with a specific ophthalmopathic immunoglobulin that reacts with retro-orbital antigen as distinct from thyroid antigens, and that the autoimmune response is directed towards retro-orbital antigens. This suggests that the ophthalmopathy is an entity distinct from autoimmune thyroid disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6424781      PMCID: PMC1441358          DOI: 10.1136/bmj.288.6425.1183

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  19 in total

1.  Thyroid-stimulating immunoglobulins in Graves' disease.

Authors:  B R Smith; R Hall
Journal:  Lancet       Date:  1974-08-24       Impact factor: 79.321

2.  Binding of thyroglobulin and thyroglobulin-antithyroglobulin immune complex to extraocular muscle membrane.

Authors:  J Konishi; M M Herman; J P Kriss
Journal:  Endocrinology       Date:  1974-08       Impact factor: 4.736

3.  Retrobulbar modifications in experimental exophthalmos: the effect of thyrotropin and an exophthalmos producing substance derived from thyrotropin on the 35SO4 incorporation and glycosaminoglycan content of Harderian glands.

Authors:  R J Winand; L D Kohn
Journal:  Endocrinology       Date:  1973-09       Impact factor: 4.736

4.  Studies of homologous immunization with mouse harderian gland.

Authors:  S P Singh; J M McKenzie
Journal:  Metabolism       Date:  1971-03       Impact factor: 8.694

5.  Observations against a causal relationship between the long-acting thyroid stimulator and ophthalmopathy in Graves' disease.

Authors:  J M McKenzie; E P McCullagh
Journal:  J Clin Endocrinol Metab       Date:  1968-08       Impact factor: 5.958

6.  Demonstration of delayed hypersensitivity to retrobulbar and thyroid tissues in human exophthalmos.

Authors:  P Mashieu; R Winand
Journal:  J Clin Endocrinol Metab       Date:  1972-06       Impact factor: 5.958

7.  Immune exophthalmos due to harderian gland antigen.

Authors:  M A Pisarev; N Altschuler; T A Davison
Journal:  Endocrinology       Date:  1968-10       Impact factor: 4.736

8.  Failure of retro-orbital tissue to neutralize the biological activity of the long-acting thyroid stimulator.

Authors:  J Shillinglaw; R D Utiger
Journal:  J Clin Endocrinol Metab       Date:  1968-07       Impact factor: 5.958

9.  Relationships of thyrotropin to exophthalmic-producing substance. Purification of homogeneous glycoproteins containing both activities from [3H]-labeled pituitary extracts.

Authors:  R J Winand; L D Kohn
Journal:  J Biol Chem       Date:  1970-03-10       Impact factor: 5.157

10.  Cell-mediated immunity in the exophthalmos of Graves' disease as demonstrated by the migration inhibition factor (MIF) test.

Authors:  R E Munro; L Lamki; V V Row; R Volpé
Journal:  J Clin Endocrinol Metab       Date:  1973-08       Impact factor: 5.958

View more
  19 in total

1.  The use of low voltage electric therapy in the treatment of 'Graves ophthalmopathy'.

Authors:  O Fakhri
Journal:  Int Ophthalmol       Date:  1991-05       Impact factor: 2.031

Review 2.  Autoimmunity in Graves' ophthalmopathy: a review.

Authors:  A P Weetman
Journal:  J R Soc Med       Date:  1989-03       Impact factor: 5.344

3.  Ophthalmopathic immunoglobulin not detected in patients with Graves' ophthalmopathy.

Authors:  K Bjelkenkrantz; A Karlsson; I Mendel-Hartvig; T H Tötterman
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-14

Review 4.  The harderian gland: its tumors and its relevance to humans.

Authors:  D M Albert; W C Frayer; H E Black; S J Massicotte; D N Sang; J Soque
Journal:  Trans Am Ophthalmol Soc       Date:  1986

Review 5.  Polyglandular autoimmune syndrome: current concepts.

Authors:  J Meyerson; E E Lechuga-Gomez; P E Bigazzi; P G Walfish
Journal:  CMAJ       Date:  1988-04-01       Impact factor: 8.262

6.  Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy.

Authors:  P Kendall-Taylor; A L Crombie; A M Stephenson; M Hardwick; K Hall
Journal:  BMJ       Date:  1988-12-17

7.  Clinical significance of a new autoantibody against a human eye muscle soluble antigen, detected by immunofluorescence.

Authors:  M Mengistu; E Laryea; A Miller; J R Wall
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

8.  The influence of surgery on endocrine ophthalmopathy.

Authors:  A Frilling; P E Goretzki; M Grussendorf; M Erbslöh; H D Röher
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

Review 9.  Graves' ophthalmopathy.

Authors:  W E Barrie
Journal:  West J Med       Date:  1993-06

10.  A study of the binding of Graves' immunoglobulins to orbital antigens.

Authors:  K Banovac; S Levis; S F Byrne
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.